Rational Design of Small-Molecule Stabilizers of Spermine Synthase Dimer by Virtual Screening and Free Energy-Based Approach

Snyder-Robinson Syndrome (SRS) is a rare mental retardation disorder which is caused by the malfunctioning of an enzyme, the spermine synthase (SMS), which functions as a homo-dimer. The malfunctioning of SMS in SRS patients is associated with several identified missense mutations that occur away from the active site. This investigation deals with a particular SRS-causing mutation, the G56S mutation, which was shown computationally and experimentally to destabilize the SMS homo-dimer and thus to abolish SMS enzymatic activity. As a proof-of-concept, we explore the possibility to restore the enzymatic activity of the malfunctioning SMS mutant G56S by stabilizing the dimer through small molecule binding at the mutant homo-dimer interface. For this purpose, we designed an in silico protocol that couples virtual screening and a free binding energy-based approach to identify potential small-molecule binders on the destabilized G56S dimer, with the goal to stabilize it and thus to increase SMS G56S mutant activity. The protocol resulted in extensive list of plausible stabilizers, among which we selected and tested 51 compounds experimentally for their capability to increase SMS G56S mutant enzymatic activity. In silico analysis of the experimentally identified stabilizers suggested five distinctive chemical scaffolds. This investigation suggests that druggable pockets exist in the vicinity of the mutation sites at protein-protein interfaces which can be used to alter the disease-causing effects by small molecule binding. The identified chemical scaffolds are drug-like and can serve as original starting points for development of lead molecules to further rescue the disease-causing effects of the Snyder-Robinson syndrome for which no efficient treatment exists up to now.

[1]  Heather A Carlson,et al.  Protein flexibility and species specificity in structure-based drug discovery: dihydrofolate reductase as a test system. , 2007, Journal of the American Chemical Society.

[2]  A. Pegg,et al.  Effect of spermine synthase on the sensitivity of cells to anti-tumour agents. , 2003, The Biochemical journal.

[3]  M. Bewley,et al.  Aminopropyltransferases: function, structure and genetics. , 2006, Journal of biochemistry.

[4]  Harrison J. Hocker,et al.  Novel Allosteric Sites on Ras for Lead Generation , 2011, PloS one.

[5]  Peter T Lansbury,et al.  Small-molecule-mediated stabilization of familial amyotrophic lateral sclerosis-linked superoxide dismutase mutants against unfolding and aggregation. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[6]  R. Fåhraeus,et al.  In silico-in vitro screening of protein-protein interactions: towards the next generation of therapeutics. , 2008, Current pharmaceutical biotechnology.

[7]  Ozlem Keskin,et al.  Integrating Structure to Protein-Protein Interaction Networks That Drive Metastasis to Brain and Lung in Breast Cancer , 2013, PloS one.

[8]  Emil Alexov,et al.  Modeling effects of human single nucleotide polymorphisms on protein-protein interactions. , 2009, Biophysical journal.

[9]  C. Ishioka,et al.  Locus-specific mutation databases: pitfalls and good practice based on the p53 experience , 2006, Nature Reviews Cancer.

[10]  David S. Goodsell,et al.  AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility , 2009, J. Comput. Chem..

[11]  Sylvain Rault,et al.  Targeting the proangiogenic VEGF-VEGFR protein-protein interface with drug-like compounds by in silico and in vitro screening. , 2011, Chemistry & biology.

[12]  Janice Rowe,et al.  A CDKN2A mutation in familial melanoma that abrogates binding of p16INK4a to CDK4 but not CDK6. , 2007, Cancer research.

[13]  A. Fersht,et al.  Toward the rational design of p53-stabilizing drugs: probing the surface of the oncogenic Y220C mutant. , 2010, Chemistry & biology.

[14]  A. Pegg.  Mammalian polyamine metabolism and function , 2009, IUBMB life.

[15]  C. Skinner,et al.  X-linked spermine synthase gene (SMS) defect: the first polyamine deficiency syndrome , 2003, European Journal of Human Genetics.

[16]  Pierre Tufféry,et al.  The FAF-Drugs2 server: a multistep engine to prepare electronic chemical compound collections , 2011, Bioinform..

[17]  Zhe Zhang,et al.  A Y328C missense mutation in spermine synthase causes a mild form of Snyder-Robinson syndrome. , 2013, Human molecular genetics.

[18]  Dan L. Sackett,et al.  Protein-protein interactions: making drug design second nature. , 2009, Nature chemistry.

[19]  J. Śanchez-Corona,et al.  A missense mutation, p.V132G, in the X‐linked spermine synthase gene (SMS) causes Snyder–Robinson syndrome , 2009, American journal of medical genetics. Part A.

[20]  Olivier Sperandio,et al.  Design of protein–membrane interaction inhibitors by virtual ligand screening, proof of concept with the C2 domain of factor V , 2007, Proceedings of the National Academy of Sciences.

[21]  D. Geerts,et al.  The polyamine metabolism genes ornithine decarboxylase and antizyme 2 predict aggressive behavior in neuroblastomas with and without MYCN amplification , 2010, International journal of cancer.

[22]  Philippe Roche,et al.  Chemical and structural lessons from recent successes in protein-protein interaction inhibition (2P2I). , 2011, Current opinion in chemical biology.

[23]  Z. Xiang,et al.  Extending the accuracy limits of prediction for side-chain conformations. , 2001, Journal of molecular biology.

[24]  Lei Deng,et al.  PrePPI: a structure-informed database of protein–protein interactions , 2012, Nucleic Acids Res..

[25]  Christopher L. McClendon,et al.  Reaching for high-hanging fruit in drug discovery at protein–protein interfaces , 2007, Nature.

[26]  Barry Honig,et al.  Extending the accuracy limits of prediction for side-chain conformations. , 2001 .

[27]  Philippe Roche,et al.  2P2Idb: a structural database dedicated to orthosteric modulation of protein–protein interactions , 2012, Nucleic Acids Res..

[28]  E. Alexov,et al.  Combining conformational flexibility and continuum electrostatics for calculating pK(a)s in proteins. , 2002, Biophysical journal.

[29]  Ajay N. Jain.  Surflex-Dock 2.1: Robust performance from ligand energetic modeling, ring flexibility, and knowledge-based search , 2007, J. Comput. Aided Mol. Des..

[30]  David Lagorce,et al.  Tyrosine Kinase Syk Non-Enzymatic Inhibitors and Potential Anti-Allergic Drug-Like Compounds Discovered by Virtual and In Vitro Screening , 2011, PloS one.

[31]  Jacqueline Cherfils,et al.  Structure-based discovery of an inhibitor of Arf activation by Sec7 domains through targeting of protein–protein complexes , 2007, Proceedings of the National Academy of Sciences.

[32]  R. Maki,et al.  Mutation analysis of the Pip interaction domain reveals critical residues for protein-protein interactions. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[33]  T. Braulke,et al.  Missense mutation in the N‐acetylglucosamine‐1‐phosphotransferase gene (GNPTA) in a patient with mucolipidosis II induces changes in the size and cellular distribution of GNPTG , 2006, Human mutation.

[34]  Jianpeng Ma,et al.  CHARMM: The biomolecular simulation program , 2009, J. Comput. Chem..

[35]  A. Shirahata,et al.  Effects of inhibitors of spermidine synthase and spermine synthase on polyamine synthesis in rat tissues. , 1993, Biochemical pharmacology.

[36]  Kathrin Heikamp,et al.  The Future of Virtual Compound Screening , 2013, Chemical biology & drug design.

[37]  Zhe Zhang,et al.  In Silico and In Vitro Investigations of the Mutability of Disease-Causing Missense Mutation Sites in Spermine Synthase , 2011, PloS one.

[38]  Alexander Tropsha,et al.  Discrete Molecular Dynamics Distinguishes Nativelike Binding Poses from Decoys in Difficult Targets , 2022 .

[39]  Daniel Kuhn,et al.  Combining Global and Local Measures for Structure-Based Druggability Predictions , 2012, J. Chem. Inf. Model..

[40]  A. Chakravarti,et al.  Design, synthesis and biological studies of survivin dimerization modulators that prolong mitotic cycle. , 2013, Bioorganic & medicinal chemistry letters.

[41]  Zachary A. Szpiech,et al.  High-resolution network biology: connecting sequence with function , 2013, Nature Reviews Genetics.

[42]  E. Gerner,et al.  Polyamines and cancer: old molecules, new understanding , 2004, Nature Reviews Cancer.

[43]  Alan F. Scott,et al.  Online Mendelian Inheritance in Man (OMIM), a knowledgebase of human genes and genetic disorders , 2002, Nucleic Acids Res..

[44]  B. Villoutreix,et al.  In Silico Mechanistic Profiling to Probe Small Molecule Binding to Sulfotransferases , 2013, PloS one.

[45]  E. Alexov,et al.  Calculated protein and proton motions coupled to electron transfer: electron transfer from QA- to QB in bacterial photosynthetic reaction centers. , 1999, Biochemistry.

[46]  Olivier Sperandio,et al.  How to choose relevant multiple receptor conformations for virtual screening: a test case of Cdk2 and normal mode analysis , 2010, European Biophysics Journal.

[47]  Arthur J. Olson,et al.  AutoDock Vina: Improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading , 2009, J. Comput. Chem..

[48]  C. Schwartz,et al.  New SMS mutation leads to a striking reduction in spermine synthase protein function and a severe form of Snyder–Robinson X-linked recessive mental retardation syndrome , 2008, Journal of Medical Genetics.

[49]  Olivier Sperandio,et al.  Editorial: [Hot Topics: Toward the Design of Drugs on Protein-Protein Interactions] , 2012 .

[50]  A. Surolia,et al.  Crystallographic Study of Novel Transthyretin Ligands Exhibiting Negative-Cooperativity between Two Thyroxine Binding Sites , 2012, PloS one.

[51]  A. Pegg,et al.  Determination of Cellular Aminopropyltransferase Activity Using Precolumn Fluorescent Etheno-Derivatization with High-Performance Liquid Chromatography , 2012, Analytical sciences : the international journal of the Japan Society for Analytical Chemistry.

[52]  S. Teague.  Implications of protein flexibility for drug discovery , 2003, Nature Reviews Drug Discovery.

[53]  E. Alexov,et al.  Approaches and resources for prediction of the effects of non-synonymous single nucleotide polymorphism on protein function and interactions. , 2008, Current pharmaceutical biotechnology.

[54]  Olivier Sperandio,et al.  One hundred thousand mouse clicks down the road: selected online resources supporting drug discovery collected over a decade. , 2013, Drug discovery today.

[55]  David K. Johnson,et al.  Druggable Protein Interaction Sites Are More Predisposed to Surface Pocket Formation than the Rest of the Protein Surface , 2013, PLoS Comput. Biol..

[56]  A. Robinson,et al.  Recessive Sex-Linked Mental Retardation in the Absence of Other Recognizable Abnormalities , 1969, Clinical pediatrics.

[57]  Zhe Zhang,et al.  Research and applications: A rational free energy-based approach to understanding and targeting disease-causing missense mutations , 2013, J. Am. Medical Informatics Assoc..

[58]  Tom L. Blundell,et al.  Does a More Precise Chemical Description of Protein–Ligand Complexes Lead to More Accurate Prediction of Binding Affinity? , 2014, J. Chem. Inf. Model..

[59]  Jun Chen,et al.  Discovery of a novel small molecule binding site of human survivin. , 2007, Bioorganic & medicinal chemistry letters.

[60]  Andreas Bender,et al.  Recognizing Pitfalls in Virtual Screening: A Critical Review , 2012, J. Chem. Inf. Model..

[61]  Scott A. Peterson,et al.  Inhibiting transthyretin amyloid fibril formation via protein stabilization. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[62]  Holger Gohlke,et al.  Hot Spots and Transient Pockets: Predicting the Determinants of Small-Molecule Binding to a Protein-Protein Interface , 2012, J. Chem. Inf. Model..

[63]  Urs Haberthür,et al.  FACTS: Fast analytical continuum treatment of solvation , 2008, J. Comput. Chem..

[64]  Peter Loppnau,et al.  Crystal Structure of Human Spermine Synthase , 2008, Journal of Biological Chemistry.

[65]  C. Dobson.  Protein folding and misfolding , 2003, Nature.

[66]  Jens Carlsson,et al.  Predicting binding modes from free energy calculations. , 2008, Journal of medicinal chemistry.

[67]  VINCENT ZOETE,et al.  SwissParam: A fast force field generation tool for small organic molecules , 2011, J. Comput. Chem..

[68]  Tina Ritschel,et al.  Current progress in Structure-Based Rational Drug Design marks a new mindset in drug discovery , 2018 .

[69]  Frank M Boeckler,et al.  Targeted rescue of a destabilized mutant of p53 by an in silico screened drug , 2008, Proceedings of the National Academy of Sciences.

[70]  M. Sternberg,et al.  The effects of non-synonymous single nucleotide polymorphisms (nsSNPs) on protein-protein interactions. , 2013, Journal of molecular biology.

[71]  Peter Gruber,et al.  Modulators of protein-protein interactions: novel approaches in targeting protein kinases and other pharmaceutically relevant biomolecules. , 2011, Current topics in medicinal chemistry.

[72]  Junjun Mao,et al.  MCCE2: Improving protein pKa calculations with extensive side chain rotamer sampling , 2009, J. Comput. Chem..

[73]  António J. M. Ribeiro,et al.  Protein-ligand docking in the new millennium--a retrospective of 10 years in the field. , 2013, Current medicinal chemistry.

[74]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[75]  Olivier Sperandio,et al.  Rational design of small molecules targeting the C2 domain of coagulation factor VIII. , 2014, Blood.

[76]  C. Ottmann,et al.  Small-molecule stabilization of protein-protein interactions: an underestimated concept in drug discovery? , 2012, Angewandte Chemie.

[77]  Philip E. Bourne,et al.  The RCSB PDB information portal for structural genomics , 2005, Nucleic Acids Res..

[78]  Olivier Sperandio,et al.  Identification of novel small molecule inhibitors of activated protein C. , 2014, Thrombosis research.

[79]  Michelle R. Arkin,et al.  Small-molecule inhibitors of protein–protein interactions: progressing towards the dream , 2004, Nature Reviews Drug Discovery.

[80]  Gerhard Klebe,et al.  Strategies to search and design stabilizers of protein–protein interactions: A feasibility study , 2007, Proteins.

[81]  Lin Wang,et al.  Analyzing Effects of Naturally Occurring Missense Mutations , 2012, Comput. Math. Methods Medicine.

[82]  Zhe Zhang,et al.  Computational analysis of missense mutations causing Snyder‐Robinson syndrome , 2010, Human mutation.

[83]  Olivier Sperandio,et al.  iPPI-DB: a manually curated and interactive database of small non-peptide inhibitors of protein-protein interactions. , 2013, Drug discovery today.

[84]  L. Loeb,et al.  Mutation at the Polymerase Active Site of Mouse DNA Polymerase δ Increases Genomic Instability and Accelerates Tumorigenesis , 2007, Molecular and Cellular Biology.